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ORIGINAL INVESTIGATION
Greater glucagon-like peptide-1 responses 
to oral glucose are associated with lower central 
and peripheral blood pressures
Julie R. Lundgren1,2* , Kristine Færch3, Daniel R. Witte4,6, Anna E. Jonsson2, Oluf Pedersen2, Torben Hansen2, 
Torsten Lauritzen5, Jens J. Holst1,2, Dorte Vistisen3, Marit E. Jørgensen3, Signe S. Torekov1,2*†  
and Nanna B. Johansen3,6†
Abstract 
Background and aim: Cardiovascular diseases (CVDs) are globally the leading cause of death and hypertension is 
a significant risk factor. Treatment with glucagon-like peptide-1 (GLP-1) receptor agonists has been associated with 
decreases in blood pressure and CVD risk. Our aim was to investigate the association between endogenous GLP-1 
responses to oral glucose and peripheral and central haemodynamic measures in a population at risk of diabetes and 
CVD.
Methods: This cross-sectional study included 837 Danish individuals from the ADDITION-PRO cohort (52% men, 
median (interquartile range) age 65.5 (59.8 to 70.7) years, BMI 26.1 (23.4 to 28.5) kg/m2, without antihypertensive treat-
ment and known diabetes). All participants received an oral glucose tolerance test with measurements of GLP-1 at 0, 
30 and 120 min. Aortic stiffness was assessed by pulse wave velocity (PWV). The associations between GLP-1 response 
and central and brachial blood pressure (BP) and PWV were assessed in linear regression models adjusting for age and 
sex.
Results: A greater GLP-1 response was associated with lower central systolic and diastolic BP of − 1.17 mmHg 
(95% confidence interval (CI) − 2.07 to − 0.27 mmHg, P = 0.011) and − 0.74 mmHg (95% CI − 1.29 to − 0.18 mmHg, 
P = 0.009), respectively, as well as lower brachial systolic and diastolic BP of − 1.27 mmHg (95% CI − 2.20 to 
− 0.33 mmHg, P = 0.008) and − 1.00 (95% CI − 1.56 to − 0.44 mmHg, P = 0.001), respectively. PWV was not associ-
ated with GLP-1 release (P = 0.3). Individuals with the greatest quartile of GLP-1 response had clinically relevant lower 
BP measures compared to individuals with the lowest quartile of GLP-1 response (central systolic BP: − 4.94 (95% CI 
− 8.56 to − 1.31) mmHg, central diastolic BP: − 3.05 (95% CI − 5.29 to − 0.80) mmHg, brachial systolic BP: − 5.18 (95% 
CI − 8.94 to − 1.42) mmHg, and brachial diastolic BP: − 2.96 (95% CI − 5.26 to − 0.67) mmHg).
Conclusion: Greater glucose-stimulated GLP-1 responses were associated with clinically relevant lower central and 
peripheral blood pressures, consistent with beneficial effects on the cardiovascular system and reduced risk of CVD 
and mortality.
Trial registration ClinicalTrials.gov Identifier: NCT00237549. Retrospectively registered 10 October 2005
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Background
Globally, cardiovascular diseases (CVDs) were the lead-
ing cause of death in 2017 [1]. Hypertension is a known 
risk factor of CVD and it is estimated that over 1 bil-
lion people suffers from hypertension [2]. Persons with 
uncontrolled hypertension are at increased risk of all-
cause, CVD-specific, heart disease-specific and cer-
ebrovascular disease deaths compared to normotensive 
persons (HR = 1.6, 2.2, 2.2 and 3.0, respectively) [3]. In 
recent clinical trials, treatment with glucagon-like pep-
tide-1 receptor agonists (GLP-1 RAs) decreased cardio-
vascular morbidity and/or mortality in patients with type 
2 diabetes at increased cardiovascular risk [4, 5]. Further, 
treatment with GLP-1 RAs decreases blood pressure and 
increases heart rate [6]. GLP-1 is an important incretin 
hormone which increases insulin secretion and thereby 
lowers blood glucose levels. It is secreted from the gas-
trointestinal tract by enteroendocrine L cells, upon nutri-
tional intake, and is rapidly broken down by the enzyme 
dipeptidyl peptidase-4 (DPP-4) [7]. Beyond the insulino-
tropic effects, GLP-1 has numerous other effects includ-
ing inhibition of glucagon secretion [8], inhibition of 
gastrointestinal secretion and motility [9] and reduction 
in appetite and food intake [10].
Chronic low-grade inflammation has been proposed 
to contribute to development of cardiovascular disease 
and atherosclerosis [11] and several inflammatory mark-
ers have been shown to be reduced by treatment with 
GLP-1 RA [12]. Based on a study with mice lacking the 
GLP-1 receptor (GLP-1R−/−) [13], it has been suggested 
that endogenous GLP-1 play a role in controlling the 
cardiovascular system [14]. This study showed that GLP-
1R−/− mice exhibited both structural and functional car-
diac abnormalities compared to wild type mice. Another 
study in humans, found that acute GLP-1 infusion in 
physiological concentrations (corresponding to a post-
prandial level) did not change systolic blood pressure but 
did increase heart rate, brachial artery diameter and bra-
chial artery flow velocity [15], indicating a physiologically 
relevant role of GLP-1 on vascular function.
Treatment studies with supra-physiological pharma-
cological doses of GLP-1 RAs have shown decreased 
risk of CVD [4, 5] and also a decrease in blood pressure 
[16] whereas the natural endogenous GLP-1 secretion 
and association with blood pressure measurements is 
largely unknown. Therefore, we wished to examine the 
more long term effects of endogenous GLP-1 response 
to elaborate on the cardiovascular mechanisms of GLP-1 
and to investigate whether a greater endogenous GLP-1 
response is associated with lower blood pressure. Hence, 
the aim of this study was to examine the association 
between endogenous GLP-1 response to glucose and 
peripheral and central hemodynamic measures in a large, 
Danish cohort of 837 individuals at risk of diabetes and 
thereby also at risk of cardiovascular disease.
Methods
This cross-sectional study is part of a large observational 
cohort study: the ADDITION-PRO study, a longitudi-
nal cohort study of individuals at high risk for diabetes, 
recruited from Danish primary care. A thorough descrip-
tion of the design can be found in the ADDITION-PRO 
protocol [17].
In the ADDITION-PRO study, a detailed examina-
tion programme was executed during 2009–2011, and 
2082 individuals participated. Blood sampling for GLP-1 
measurement was performed at three out of four study 
centres, comprising 1853 individuals. Of those, 252 had 
known type 2 diabetes and 15 did not fast and did not 
have an OGTT. Of the remaining 1586 participants, 657 
were taking antihypertensive medication and 92 addi-
tional participants had missing information on central 
haemodynamics or GLP-1, leaving 837 individuals avail-
able for the present analysis. No individuals were using 
incretin-based drugs. Of the 837 individuals, 116 were 
using lipid-lowering drugs, which we allowed in the pre-
sent analysis.
Peripheral and central haemodynamics
Brachial blood pressure was measured three times with 
the participant in a sitting position after 10  min of rest 
(Omron M6 comfort, Omron Healthcare, Milton Keynes, 
UK) and reported as an average. Aortic pulse wave veloc-
ity (PWV) and central blood pressure were assessed with 
the participant in a supine position after 10 min of rest 
using a SphygmoCor apparatus (version 8, Atcor Medi-
cal, West Ryde, NSW, Australia) and a tonometer, which 
captured wave forms at the carotid, femoral and radial 
artery. Using simultaneous ECG monitoring, the time 
from the R wave to the arrival of the pulse wave at the 
carotid and femoral artery, respectively, was captured. 
An anthropometer (Seca, Medical Scales and Measur-
ing Systems, Hamburg, Germany) was used to measure 
the distance from the suprasternal point to the carotid 
artery recording site and from the suprasternal point to 
the femoral artery recording site to avoid overestimation 
of the distance. The ratio between the distance and the 
time defined the PWV. The PWV was measured twice 
between the right carotid and right femoral artery and in 
case of a difference of more than 0.5 m/s, a third measure 
was taken. It was reported as an average of the two clos-
est measures. Peripheral pressure waveforms assessed 
at the radial artery were used to estimate central blood 
pressure [17]. The average of two measures were used.
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Biochemical measures
A 3-point standard 75  g oral glucose tolerance test 
(OGTT) was performed, with blood sampling before 
(0  min) and 30 and 120  min after glucose intake. 
Plasma glucose was measured using one of two differ-
ent methods; Hitachi 912 system (Roche Diagnostics, 
Mannheim, Germany) or Vitros 5600 system (Ortho 
Clinical Diagnostics, Illkirch Cedex, France). Subse-
quently, Vitros values were converted to Hitachi values 
[18]. HbA1c was measured by high-performance liq-
uid chromatography (TOSOH G7, Tokyo, Japan) [18]. 
Plasma levels of total GLP-1 (intact and metabolites) 
were measured in EDTA plasma stored at − 80 °C using 
RIA with analytical detection limit around 1 pmol/l and 
with intra- and interassay coefficients of variation of 
6.0% and 15%. To diminish methodological variances, 
all samples were analysed after study completion dur-
ing 2 consecutive months. Furthermore, quality con-
trols and batches for all reagents were identical for all 
sets [18].
Statistics
GLP-1 response was defined as the incremental area 
under the curve (iAUC), from start of the OGTT to 
120 min after glucose intake, using the GLP-1 measure-
ments before glucose intake and after 30 and 120  min. 
Using the trapezoid rule, iAUC was calculated as total 
area under the curve subtracted the fasting GLP-1 
value × 120 min (participants with iAUC ≤ 0 are excluded 
from analyses). Associations between GLP-1 release and 
central haemodynamics were analysed in separate models 
using linear regression analysis. Prior to analysis, iAUC 
for GLP-1(iAUC GLP-1) was  log2-transformed to fulfil the 
requirement of a normal distribution of the model resid-
uals. All analyses were adjusted for age and sex. Analyses 
of PWV were additionally adjusted for mean blood pres-
sure and heart rate at time of PWV measurement. Addi-
tional analyses adjusting for age, sex and either iAUC 
insulin, fasting plasma glucose, BMI or HOMA-IR were 
performed for association between iAUC GLP-1 and 
central and brachial blood pressures. The study popula-
tion was categorized into quartiles according to the iAUC 
GLP-1 response and the lowest and highest quartiles 
were compared with regards to blood pressure measures 
(adjusting for age and sex). Sub-analysis of the study pop-
ulation was made dividing the population into a normo 
glucose (fasting glucose < 5.6  mmol/l) group and a pre-
diabetes risk (fasting glucose ≥ 5.6  mmol/l) group and 
association to blood pressures were investigated (adjust-
ing for age and sex). Analyses were performed using SAS 
version 9.4 (SAS Institute, Cary, NC, USA) and figures 
were created in R version 3.2.2 (The R Foundation for 
Statistical Computing). A P-value of < 0.05 was consid-
ered significant.
Results
The 837 individuals included for analysis had a median 
(interquartile range) age of 65.5 (59.8 to 70.7) years and 
47.7% were women, BMI of 26.1  (23.4 to 28.5)  kg/m2, 
fasting glucose concentration of 5.9 (5.5 to 6.3) mmol/l, 
HbA1c level of 5.6 (5.4 to 5.8) % and a median blood 
pressure within the normal range (brachial systolic blood 
pressure of 130 (118.3 to 142) mmHg and diastolic blood 
pressure of 80 (73.3 to 87.0)  mmHg), Table  1. OGTT 
responses of GLP-1, glucose and insulin are shown in 
Fig. 1.
A greater GLP-1 response during the OGTT (iAUC 
GLP-1) was associated with a lower central systolic 
(− 1.17  mmHg; P = 0.011) and diastolic (− 0.74  mmHg; 
P = 0.009) blood pressure as well as a lower bra-
chial systolic (− 1.27  mmHg; P = 0.008) and diastolic 
(− 1.00 mmHg; P = 0.001) blood pressure. Central pulse 
pressure and brachial pulse pressure were not signifi-
cantly associated with GLP-1 secretion, Table  2 and 
Fig. 2.
A doubling in iAUC GLP-1 resulted in a non-significant 
difference in PWV of − 0.04 m/s (P = 0.3).
Analyses were adjusted for age and sex and PWV 
analyses was additionally adjusted for blood pres-
sure and heart rate. The association between GLP-1 
response and central and peripheral blood pressure 
remained significant when adjusting for fasting glu-
cose, iAUC insulin response, and for HOMA-IR (with 
Table 1 Characteristics
Characteristics of the study population. IQR interquartile range, BMI body mass 
index, HbA1c glycated haemoglobin, GLP-1 glucagon-like peptide-1
Characteristics Median IQR or n (%)
Age (years) 65.5 (59.8; 70.7)
Women, n (%) 399 (47.7)
BMI (kg/m2) 26.1 (23.4; 28.5)
Fasting plasma glucose (mmol/l) 5.9 (5.5; 6.3)
HbA1c (%) 5.6 (5.4; 5.8)
Fasting serum insulin (pmol/l) 34.0 (23.0; 51.0)
Fasting GLP-1 (pmol/l) 12.0 (8.0; 15.0)
Pulse wave velocity (m/s) 7.6 (6.6; 8.9)
Central systolic blood pressure (mmHg) 120.5 (110.3; 132.3)
Central diastolic blood pressure (mmHg) 78.0 (71.5; 85.0)
Central pulse pressure (mmHg) 41.5 (35.5; 50.2)
Brachial systolic blood pressure (mmHg) 130.3 (118.3; 142.0)
Brachial diastolic blood pressure (mmHg) 80.0 (73.3; 87.0)
Brachial pulse pressure (mmHg) 49.7 (41.7; 57.7)
Heart rate (beats/min) 61.3 (55.5; 67.8)
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the exception of central diastolic blood pressure) (in 
separate analyses). When adjusting for BMI, the asso-
ciation remained significant for central systolic blood 
pressure and peripheral diastolic blood pressure, 
Fig.  2. Sub-analysis of individuals with normal fasting 
glucose (fasting glucose level < 5.6  mmol/l, n = 270) 
and of individuals with pre-diabetes (fasting glucose 
level ≥ 5.6  mmol/l, n = 567) did not reach statistical 
significance and there was no significant difference 
between the groups.
Greater GLP‑1 response is associated with ~ 5 mmHg lower 
blood pressure compared to individuals with lower GLP‑1 
response
The participants were divided into quartiles accord-
ing to their iAUC GLP-1 response. The group with the 
highest quartile of GLP-1 response was associated with 
significant lower central systolic (− 4.94 (95% CI − 8.56 
to − 1.31) mmHg) and diastolic (− 3.05 (95% CI − 5.29 
to − 0.80) mmHg) blood pressure as well as significant 
lower brachial systolic (− 5.18 (95% CI − 8.94 to − 1.42) 
Fig. 1 Oral glucose tolerance test (OGTT) responses of glucagon-like peptide-1 (GLP-1), glucose and insulin. Median is shown by a square and 
brackets show interquartile range
Table 2 Haemodynamic measurements
Estimated difference in blood pressure measurements and PWV for a doubling in iAUC of GLP-1. P-values < 0.05 are italicized
a Adjusted for age and sex
b Additionally adjusted for heart rate and mean blood pressure during the PWV measurement
Measurement Estimate (mmHg) 95% confidence interval (mmHg) P value
Central systolic blood  pressurea − 1.17 − 2.07 to − 0.27 0.0109
Central diastolic blood  pressurea − 0.74 − 1.29 to − 0.18 0.0089
Central pulse  pressurea − 0.43 − 1.03 to 0.17 0.2
Brachial systolic blood  pressurea − 1.27 − 2.20 to − 0.33 0.0081
Brachial diastolic blood  pressurea − 1.00 − 1.56 to − 0.44 0.0005
Brachial pulse  pressurea − 0.27 − 0.88 to 0.35 0.4
Pulse wave  velocityb − 0.04 − 0.13 to 0.04 0.3
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mmHg) and diastolic (− 2.96 (95% CI − 5.26 to − 0.67) 
mmHg) blood pressure, compared to the group with the 
lowest quartile of GLP-1 response.
Discussion
This study of 837 people at risk of diabetes and thereby 
CVD shows that there is a clinically relevant relationship 
between greater endogenous GLP-1 hormone response 
during an OGTT and lower blood pressure measures in 
a normotensive population. The quartile of individuals 
with the highest GLP-1 response had a ~ 5 mmHg lower 
blood pressure compared to the quartile of individuals 
with the lowest GLP-1 response. This degree of blood 
pressure lowering has been associated with lower risk of 
cardiovascular event, all-cause mortality and cardiovas-
cular mortality. Thus indicating beneficial effects on the 
cardiovascular system with greater endogenous GLP-1 
secretion in agreement with the observations of lower 
cardiovascular mortality and decreased blood pressure 
with GLP-1 RA treatment [4, 5, 16].
Possible mechanisms of blood pressure lowering action 
of GLP‑1 RA
Several parameters have been proposed to affect the 
secretion and concentration of GLP-1 including glucose 
[19], fat [19], bile acids [20], inflammatory markers [21, 
22], 3-deoxyglucosone [23] (generated from carbohy-
drates) and the presence of obesity [24] and type 2 dia-
betes [18].
We find that there is an association between a greater 
GLP-1 response during an OGTT and lower central and 
peripheral blood pressure. Our results remain significant 
even after adjusting for iAUC insulin, fasting glucose, and 
for most analyses also for BMI and HOMA-IR, which 
are all factors known to have an impact on GLP-1 secre-
tion. Interestingly, when dividing participants into quar-
tiles according to their GLP-1 response we found that 
the group with the highest GLP-1 response was associ-
ated with approximately 5 mmHg lower blood pressures 
compared to the group with the lowest GLP-1 response. 
Many individuals with obesity and/or type 2 diabetes 
have decreased GLP-1 secretion [18, 24, 25] and these 
Fig. 2 Estimated difference in blood pressure measures in 837 individuals for a doubling in incremental AUC (iAUC) of GLP-1. HOMA-IR homeostatic 
model assessment for insulin resistance, BMI body mass index
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individuals also often have increased blood pressure [26, 
27]. Furthermore, weight loss increases GLP-1 response 
and decreases blood pressure [25, 28]. Thus, according to 
our results, it could be speculated whether the decreased 
GLP-1 response could contribute to the increased blood 
pressure in this population. Together with our analyses 
adjusted for several parameters, this implies that endog-
enous GLP-1 may have an effect on blood pressure in a 
dose–response dependent manner with the greater the 
GLP-1 response the lower the blood pressure as also 
observed for the dose-response dependently lowering of 
blood glucose [29, 30].
Clinical implications
We observe that the quartile of individuals with the high-
est GLP-1 response have a ~ 5 mmHg lower blood pres-
sure compared to the quartile of individuals with the 
lowest GLP-1 response. A large meta-analysis found that 
the degree of blood pressure reduction was proportional 
to the risk of major cardiovascular disease events, stroke, 
heart failure, and all-cause mortality [31]. Interestingly, 
a reduction of 4.5  mmHg in systolic blood pressure 
has been associated with lower risk of cardiovascular 
event, all-cause mortality and cardiovascular mortality 
[32]. Thus our finding of a 5 mmHg difference in blood 
pressure between GLP-1 response groups is of clini-
cal relevance with regards to mortality. In comparison, 
DPP-4 inhibitors reduce systolic blood pressure by 2.5–
2.8 mmHg [33–35] and GLP-1 RAs reduce systolic blood 
pressure by 1.2–4 mmHg [4, 5, 36]. GLP-1 RAs [4, 5, 37] 
have, furthermore been found to reduce risk of major 
adverse cardiac events which has not been observed for 
DPP-4 inhibitors [38–40].
The GLP-1 receptor has been located on endothelial 
cells in the vasculature [41] and a direct effect of GLP-1 
on vascular smooth muscle has also been proposed [42]. 
This may be one of the mechanisms by which GLP-1 RA 
treatment decreases blood pressure. Endothelial dysfunc-
tion, characterized by reduced nitric oxide (NO) produc-
tion, is a precursor of atherosclerosis and a risk factor for 
CVD [43]. GLP-1 treatment promotes vasodilation by 
production of NO [44]. Insulin has also been shown to 
induce NO production [45], however, the association in 
our study remained significant when adjusting the analy-
ses for insulin (see Fig.  2), indicating that GLP-1 works 
independently of insulin on the blood pressure-lowering 
mechanism. Infusion of GLP-1 in physiological doses 
exerted vasodilatory actions, decreased diastolic blood 
pressure and increased heart rate whereas systolic blood 
pressure was unchanged in a study of 26 healthy individ-
uals [15]. Furthermore, treatment with GLP-1 RAs have 
shown to improve arterial stiffness in type 2 diabetes 
[46], which is augmented by hypertension [47]. Similarly, 
treatment with DPP-4 inhibitors have shown to improve 
intima-media thickness [48], arterial stiffness [49] and 
diastolic dysfunction [50, 51], which are all factors asso-
ciated with blood pressure [52, 53]. In our study of indi-
viduals without diabetes and hypertension we did not 
find an association between GLP-1 response and PWV 
(Table 2), a measurement of arterial stiffness, or central 
pulse pressure (Fig.  2), which is determined by arterial 
stiffness [47]. To further support the effect of GLP-1 RAs 
on endothelial cells, liraglutide has also been found to 
have anti-restenotic effects mediated by endothelial NO 
[54]. Endothelial cells do not only play a role in NO pro-
duction, they also influence on the angiogenesis process 
[55] and liraglutide has been found to promote angiogen-
esis after stroke [56] opening up for the possibility that 
GLP-1-based treatment potentially could be applied as a 
neuroprotective drug as well as a cardioprotective, anti-
hyperglycemic and anti-obesity drug.
Other studies with endogenous GLP‑1 levels
Only few studies have previously analysed the association 
between endogenous GLP-1 levels and cardiovascular 
disease. In agreement with our findings, an inverse cor-
relation (r = − 0.26, P = 0.0085) between GLP-1 secretion 
and systolic blood pressure was found by Yoshihara et al. 
[57]. However, active GLP-1 (the levels of which are most 
often below detection levels of the assays) rather than 
total GLP-1 was measured in this study of 103 individu-
als with an ELISA kit. Another study reported a positive 
association between levels of GLP-1 and coronary artery 
disease [58]. However blood samples were gathered ran-
domly, i.e. not necessarily in a fasting state, from 303 per-
sons and GLP-1 levels (active GLP-1 and metabolites) 
were measured by ELISA in serum. Since random blood 
sampling is a major limitation to the study above compa-
rability to other studies is likely to be difficult. Further-
more, it is worth noting that the specificity, sensitivity, 
and validity can vary considerably between the ELISA 
kits available for GLP-1 analyses [59].
Strengths and limitations
Our physiological study includes more than 800 partici-
pants making its size a major strength, outnumbering 
previous studies [57, 58]. Total GLP-1 (not active/intact 
GLP-1) was measured with the use of a well-documented 
RIA with high specificity and sensitivity [60]. Measuring 
GLP-1 in this manner provides more information than 
solely measuring intact GLP-1 as GLP-1 metabolites also 
are included in the analyses [18]. Because of the rapid 
metabolism of the hormone, estimation of its secretion 
must be made with an assay for total GLP-1. A limita-
tion of this study, however, is the cross-sectional design, 
allowing us to find associations between GLP-1 and 
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central and peripheral haemodynamic measures whereas 
we cannot conclude on causality. However, our findings 
are in agreement with observations from GLP-1 treat-
ment studies on lowering hypertension and cardiovascu-
lar mortality [4, 5]. Haemodynamic measurements were 
collected only in a fasting state. Therefore, it was not pos-
sible to investigate the acute effects of GLP-1 secretion 
on blood pressure and PWV. Other studies have found 
no change [61] or increase [62] in blood pressure after 
acute infusion of GLP-1. In general, there does not seem 
to be consensus about whether blood pressure changes 
during an OGTT. One study found an elevation in sys-
tolic blood pressure of more than 4 mmHg after glucose 
load [63] while other studies find either small increases 
[64] or no differences [65]. Lastly, our sub-analysis divid-
ing participants into a normal fasting glucose group and 
a pre-diabetes group did not reveal any significant differ-
ences between the groups, which may be due to the lower 
number of participants in each group.
Conclusion
We found that greater glucose-stimulated GLP-1 
responses were associated with clinically relevant lower 
central and peripheral blood pressure. Thus, it is likely 
that endogenous GLP-1 response has a beneficial impact 
on vascular function, consistent with beneficial effects on 
the cardiovascular system and reduced risk of CVD and 
mortality.
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